
Kohei Shitara/X
Jun 15, 2025, 08:16
Kohei Shitara: Pleased To Report FGFR2b Expression In Gastric Cancer and Relationship With Other Biomarkers Published in ESMO Open
Kohei Shitara, Medical Oncologist at National Cancer Center Hospital East, Japan, shared a post on X:
“Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers in ESMO Open.
The results of bemarituzumab phase 3 studies are awaited.”
Title: Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Journal: ESMO Open
Authors: S. Sato, S.L. Rhodes, Y. Aoki, I. Nakayama, T. Hashimoto, J. Hawkins, R.E. Yanes, C.-H. Chang, Y. Nakamura, A. Kawazoe, S. Mishima, D. Kotani, Y. Kuboki, H. Bando, T. Kojima, S. Yoshino, S. Reading, H. Honeycutt, E. Finger, I. Endo, N. Sakamoto, T. Kuwata, T. Yoshino, K. Shitara
More posts featuring Kohei Shitara on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 07:04
Jun 15, 2025, 06:41
Jun 15, 2025, 05:57
Jun 15, 2025, 05:47
Jun 15, 2025, 05:32